No Data
No Data
No Data
No Data
No Data
Laidlaw's James Ahern Named to Crain's New York Notable Leaders in Finance 2024
NEW YORK, March 26, 2024 /PRNewswire/ -- Laidlaw & Co. Managing Partner James Ahern has been named one of Crain's New York's Notable Leaders in Finance for 2024. Mr. Ahern has been at Laidlaw for fou
PR NewswireMar 26 11:39 ET
Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating
TipRanksMar 21 02:17 ET
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 20 10:27 ET
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q4 2023 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript:Financial Performance:Business Progress:More details: Relmada Therapeutics IRTips: This article is
moomoo AIMar 19 19:33 ET · Conference Call
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
Yahoo FinanceMar 19 17:31 ET
Relmada Therapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.2 percent. This is a 34.38 percent increase over losses of
BenzingaMar 19 16:33 ET
No Data
No Data